A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
Status:
Completed
Trial end date:
2019-12-04
Target enrollment:
Participant gender:
Summary
Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's
disease patients. The proposed indication for EB8018, as an add-on therapy, will be the
treatment of adult patients suffering from Crohn's disease.